Continuous glucose monitoring (CGM) is a latest technological advancement in the field of diabetes management. CGM system is a type of device that monitors glucose by a biosensor, which is inserted through the transcutaneous or subcutaneous route. This embedded sensor measures glucose levels in interstitial fluid or blood, and transmits the information using a transmitter to a receiver/monitor to display the results. The use of CGM systems is crucial to avoid diabetic complications, as this technology can be used to periodically monitor the glucose levels. Therefore, glucose monitoring device manufacturing companies focus on the development of novel and technologically advanced CGMS. It offers a wide range of applications for all age cohorts, healthcare settings (diagnostic centers/clinics, hospital ICUs, and home healthcare), and geographies. Thus, CGMS market poses lucrative opportunities for both CGMS manufacturers and insulin pump manufacturers.
The European CGMS market generated $58 million in 2015, and is projected to reach $792 million by 2022, expanding at a CAGR of 44.9% during the forecast period. High-tech CGMS devices, such as wearable & smartphone-connected CGMS, non-invasive CGMS, smartphone-connected CGMS, and “smart” diabetes management solution (also called artificial/bionic pancreas), are expected to result in higher adoption of CGMS among endocrinologists and patients.
The market is categorized based on component, demographics, end user, and country. The component segment includes durable components such as transmitters & receivers and integrated insulin pumps; and disposable components such as sensors. Sensors occupy a dominant share in the European CGMS market owing to short life span of these devices, recurring sales of CGMS, and bulk purchases. Therefore, they are deployed in diagnostic centers/clinics. Moreover, the adoption of CGMS in hospital ICUs and in-home healthcare settings has increased in recent years. End users of CGMS devices are diabetic patients, categorized into child population (≤14 years) and adult population (>14 years).
The report includes comprehensive analysis and segmentation of different countries in Europe, including UK, France, Germany, Spain, Italy, the Netherlands, Norway, Sweden, Denmark, Finland, and rest of Europe.
Major strategies adopted by market players are collaborations, product launches, and product approvals. Agreement/partnership strategy by companies enables greater focus on innovation, distribution, and commercialization of devices. For instance, in 2016, Senseonics signed an agreement with Roche to commercialize Senseonics’ Eversense continuous glucose monitoring system. Under this agreement, Roche can sell its CGM systems in Germany, Italy, and the Netherlands
KEY MARKET BENEFITS:
KEY MARKET SEGMENTS:
By Component
By Demographics
By End User
By Country
The key players profiled in the report are listed below:
Other players in the European CGMS market include (profiles not included in the report):
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION
3.2. NEED FOR GLUCOSE MONITORING SYSTEMS
3.2.1. Diabetesa pandemic
3.2.1.1. Type 1 diabetes
3.2.1.2. Type-2 diabetes
3.2.1.3. Prediabetes and gestational diabetes mellitus (GDM)
3.2.1.4. Gestational diabetes mellitus (GDM)
3.2.1.5. Secondary diabetes
3.2.1.6. Global healthcare expenditure on diabetes
3.3. TECHNOLOGICAL ADVANCEMENTS IN CGMS
3.3.1. Smartphone-connected CGMS
3.3.1.1 Wearable and smartphone-connected CGMS
3.3.1.2. 'Smart diabetes management solutionbionic/artificial pancreas
3.3.1.3. Non-invasive CGMS
3.3.1.4. Invasive CGMS
3.3.2. CGMS: PRIME END USER SEGMENTS
3.3.2.1. CGMS: role in intensive care units (ICUs)
3.3.2.1.1. Stress hyperglycemia: common occurrence in ICUs
3.3.2.2. Non-standardization and erroneous glycemic control across ICUs
3.3.2.3. Benefits and driving factors of CGMS in ICUs
3.3.2.3.1. Use of CGMS for tight glycemic control in ICUs
3.3.2.3.2. Cost benefits due to use of CGMS
3.3.2.3.3. Lower effectiveness of POC glucometers than CGMS in ICUs
3.3.2.3.4. CGMS: most preferred by ICU staff
3.4. KEY FINDINGS
3.4.1. Top investment pockets
3.4.1.1. CGMS market, by components
3.4.2. Top winning strategies
3.5. PATENT ANALYSIS
3.6. MARKET SHARE ANALYSIS, 2015
3.7. GOVERNMENT REGULATIONS
3.7.1. ISO regulations (ISO 13485:2003)
3.7.1.1. Objective and Scope of ISO 13485:2003
3.8. EUROPE REIMBURSEMENT SCENARIO
3.8.1. Germany
3.8.2. France
3.8.3. UK
3.8.4. Spain
3.8.5. Italy
3.9. MARKET DYNAMICS
3.9.1. Drivers
3.9.1.1. Benefits of CGMS over POC glucometers
3.9.1.2. Rise in incidence of diabetes cases
3.9.1.3. Technological advancements
3.9.2. Restraints
3.9.2.1. Adverse effects and accuracy
3.9.2.2. Reimbursement and stringent regulatory issues
3.9.3. Opportunities
3.9.3.1. High adoption rate of CGMS in home healthcare and ICUs
3.9.3.2. Increase in product awareness
3.9.3.3. High undiagnosed patient population
CHAPTER 4 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. SENSORS
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. TRANSMITTERS & RECEIVERS
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.4. INTEGRATED INSULIN PUMPS
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKETBY DEMOGRAPHICS
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ADULT POPULATION (>14 YEARS)
5.2.1. Market size and forecast
5.3. CHILDREN POPULATION (14 YEARS)
5.3.1. Market size and forecast
CHAPTER 6 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. DIAGNOSTIC CENTERS/CLINICS
6.2.1. Market size and forecast
6.3. ICUS
6.3.1. Market size and forecast
6.4. HOME HEALTHCARE
6.4.1. Market size and forecast
CHAPTER 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY
7.1. OVERVIEW
7.1.1. Key market trends
7.1.2. Key growth factors and opportunities
7.1.3. Market size and forecast
7.1.4. Germany
7.1.4.1. Market size and forecast
7.1.5. France
7.1.5.1. Market size and forecast
7.1.6. UK
7.1.6.1. Market size and forecast
7.1.7. Spain
7.1.7.1. Market size and forecast
7.1.8. Italy
7.1.8.1. Market size and forecast
7.1.9. Norway
7.1.9.1. Market size and forecast
7.1.10. Sweden
7.1.10.1. Market size and forecast
7.1.11. Denmark
7.1.11.1. Market size and forecast
7.1.12. Finland
7.1.12.1. Market size and forecast
7.1.13. Netherlands
7.1.13.1. Market size and forecast
7.1.14. Rest of Europe
7.1.14.1. Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Overview
8.1.2. Operating business segments
8.1.3. Business performance
8.1.4. Key strategic moves and developments
8.2. DEXCOM, INC.
8.2.1. Overview
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. ECHO THERAPEUTICS, INC.
8.3.1. Overview
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. F. HOFFMANN-LA ROCHE LTD.
8.4.1. Overview
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.5. INSULET CORPORATION
8.5.1. Overview
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. JOHNSON & JOHNSON
8.6.1. Overview
8.6.2. Operating business segments
8.6.3. Business performance
8.6.4. Key strategic moves and developments
8.7. MEDTRONIC PLC
8.7.1. Overview
8.7.2. Operating business segments
8.7.3. Business performance
8.7.4. Key strategic moves and developments
8.8. SENSEONICS HOLDINGS, INC.
8.8.1. Overview
8.8.2. Key strategic moves and developments
LIST OF TABLES
TABLE 1. FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2016)
TABLE 2. FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2016)
TABLE 3. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 4. EUROPE CONTINUOUS GLUCOSE MONITORING SENSORS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 5. EUROPE CONTINUOUS GLUCOSE MONITORING TRANSMITTERS AND RECEIVERS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 6. EUROPE CONTINUOUS GLUCOSE MONITORING INTEGRATED INSULIN PUMPS MARKET, BY COUNTRY, 20142022 ($THOUSAND)
TABLE 7. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 8. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR ADULT POPULATION (>14YEARS), BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 9. TYPE-1 DIABETES (014 YEARS), 2015
TABLE 10. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR CHILD POPULATION (14YEARS), BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 11. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 12. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR DIAGNOSTICS/CLINICS, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 13. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR ICUS, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 14. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR HOME HEALTHCARE, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 15. PREVALENCE ESTIMATES OF DIABETES (2079 YEARS) IN EUROPE, 2015
TABLE 16. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 17. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 18. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 19. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 20. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 21. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 22. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 23. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 24. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 25. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 26. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 27. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 28. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 29. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 30. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 31. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 32. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 33. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 34. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 35. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 36. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 37. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 38. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 39. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 40. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 41. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 42. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 43. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 44. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 45. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 46. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 47. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTMES MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 48. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 49. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 50. ABBOTT: COMPANY SNAPSHOT
TABLE 51. ABBOTT: OPERATING SEGMENTS
TABLE 52. DEXCOM: COMPANY SNAPSHOT
TABLE 53. ECHO THERAPEUTICS: COMPANY SNAPSHOT
TABLE 54. ROCHE: COMPANY SNAPSHOT
TABLE 55. INSULET: COMPANY SNAPSHOT
TABLE 56. JNJ: COMPANY SNAPSHOT
TABLE 57. JNJ: OPERATING SEGMENTS
TABLE 58. MEDTRONIC: COMPANY SNAPSHOT
TABLE 59. MEDTRONIC: OPERATING SEGMENTS
TABLE 60. SENSEONICS: COMPANY SNAPSHOT
LIST OF FIGURES
FIGURE 1. PREVALENCE OF TYPE 1 DIABETES (AGE GROUP OF <15 YEARS), BY GEOGRAPHY (2015)
FIGURE 2. GLOBAL PREVALENCE OF TYPE-2 DIABETES (2014)
FIGURE 3. SIMILAR PREDISPOSITION AND RISK FACTORS FOR PREDIABETES AND TYPE-2 DIABETES
FIGURE 4. TOP TEN COUNTRIES/TERRITORIES FOR DIABETES-RELATED HEALTH EXPENDITURE, 2015
FIGURE 5. GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIGURE 6. OCCURRENCE OF HYPERGLYCEMIA IN ICUS
FIGURE 7. TOP INVESTMENT POCKETS IN CGMS, BY COMPONENTS SEGMENT
FIGURE 8. TOP WINNING STRATEGIES IN EUROPE CGMS MARKET: PERCENTAGE DISTRIBUTION (20142016)
FIGURE 9. TOP WINNING STRATEGIES IN EUROPE CGMS MARKET, BY TYPE (20142016)
FIGURE 10. PATENTS REGISTERED/APPROVED IN THE WORLD THROUGH 2016
FIGURE 11. MARKET SHARE ANALYSIS OF EUROPE CGMS MARKET, 2015
FIGURE 12. UNDIAGNOSED PATIENT POPULATION OF DIABETES, 2015 (MILLION)
FIGURE 13. ABBOTT: REVENUE, BY YEAR ($MILLION)
FIGURE 14. ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIGURE 15. ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 16. DEXCOM: REVENUE, BY YEAR ($MILLION)
FIGURE 17. DEXCOM: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 18. ECHO THERAPEUTICS: REVENUE, BY YEAR ($MILLION)
FIGURE 19. ROCHE: REVENUE, BY YEAR ($MILLION)
FIGURE 20. ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 21. INSULET: REVENUE, BY YEAR ($MILLION)
FIGURE 22. JNJ: REVENUE, BY YEAR ($MILLION)
FIGURE 23. JNJ: REVENUE, BY SEGMENT, 2015 (%)
FIGURE 24. JNJ: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 25. MEDTRONIC: REVENUE, BY YEAR ($MILLION)
FIGURE 26. MEDTRONIC: REVENUE BY SEGMENT, 2016 (%)
FIGURE 27. MEDTRONIC: REVENUE BY GEOGRAPHY, 2016 (%)
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
